Retrotransposons are genetic elements that can replicate through reverse transcription of an RNA transposition intermediate. They contribute to structural changes and, more importantly, to gene regulation. Our proprietary RNA-based, retrotransposon-mediated gene-insertion technology (RetroT™) has applications across gene-editing and delivery.
// RetroT™ GENE-EDITING
Expanding the Ability to Reverse Genetic Errors in Situ
Our retrotransposon-based approach utilizes mRNA to deliver genetic sequences and integration enzymes in a single mRNA strand. This technology offers the potential to deliver gene-sized pieces of DNA into the genome — larger than currently possible with existing gene-editing technologies.
In March 2022, Myeloid entered into an exclusive research collaboration and option agreement with Prime Medicine to develop and accelerate RetroT™.